UK markets closed
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • FTSE 250

    20,910.37
    -287.75 (-1.36%)
     
  • AIM

    1,183.25
    -8.61 (-0.72%)
     
  • GBP/EUR

    1.1532
    +0.0034 (+0.30%)
     
  • GBP/USD

    1.3922
    -0.0091 (-0.65%)
     
  • BTC-GBP

    33,328.97
    -10.61 (-0.03%)
     
  • CMC Crypto 200

    912.88
    -20.25 (-2.17%)
     
  • S&P 500

    3,811.15
    -18.19 (-0.48%)
     
  • DOW

    30,932.37
    -469.64 (-1.50%)
     
  • CRUDE OIL

    61.66
    -1.87 (-2.94%)
     
  • GOLD FUTURES

    1,733.00
    -42.40 (-2.39%)
     
  • NIKKEI 225

    28,966.01
    -1,202.26 (-3.99%)
     
  • HANG SENG

    28,980.21
    -1,093.96 (-3.64%)
     
  • DAX

    13,786.29
    -93.04 (-0.67%)
     
  • CAC 40

    5,703.22
    -80.67 (-1.39%)
     

Statement re Notice of Investor Presentation

DXS International PLC
·1-min read

DXS INTERNATIONAL PLC

(AQSE: DXSP)

Notice of Investor Presentation

DXS International plc ("DXS", the "Company"), the digital clinical decision support Company, is pleased to announce that David Immelman and Steven Bauer will provide a live presentation relating to an overview of DXS International with emphasis on ExpertCare, the new Chronic Disease Management solution which currently focuses on hypertension, via the Investor Meet Company platform on 5th March 2021 at 10:00am. The Company will also give an update on its Point-of-Care, CompleteCare and MyVytalCare products.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet the Company via:

https://www.investormeetcompany.com/dxs-international-plc/register-investor

Investors who already follow DXS International plc on the Investor Meet Company platform will automatically be invited.

The Directors of DXS International plc accept responsibility for this announcement.

Contacts:

David Immelman (Chief Executive)
DXS International plc

01252 719800
david@dxs-systems.com

https://www.dxs-systems.co.uk


Corporate Advisor

City & Merchant
David Papworth

020 7101 7676


Corporate Broker

Hybridan LLP
Claire Louise Noyce

020 3764 2341

Notes to Editors

About DXS:

DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively and which should significantly contribute towards the NHS achieving its projected efficiency savings.